Shares of Zydus Lifesciences Ltd surged more than 4% on 6 March after the company announced securing final approval from the US Food and Drug Administration (USFDA) for Dasatinib Tablets (20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg).
The tablets, which will be used to treat newly diagnosed people with chronic phase Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML), will be manufactured at the company’s Ahmedabad facility.
It is also used to treat adults with chronic, accelerated, myeloid, or lymphoid blast phase Ph+ CML, as well as adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) who are intolerant or resistant to prior treatment, such as imatinib.
Zydus Lifesciences Ltd. (SEZ) in Ahmedabad would produce the tablets.
The business also unveiled ANVIMO (Letermovir), a revolutionary treatment for kidney transplant and hematopoietic stem cell transplant (HSCT) patients that protects them from infection by the Cytomegalovirus (CMV). ANVIMO will be available in dosages of 240 mg and 480 mg.
On 4 March, the company said that it would focus on developing a vaccine that would prevent shigellosis and typhoid.
The business will carry out early-stage development, animal immunogenicity testing, and preclinical toxicity studies for this combination vaccination.
At 11:40 am, the shares of Zydus Lifescience were trading 1.88% higher at Rs 904.10 on NSE.
Curious About Zydus Lifesciences Ltd? Ask the Analyst.
Feeling overwhelmed by the markets? Let Unicorn Signals be your guide. Our user-friendly app simplifies complex data and provides actionable trading signals. Download the app today and trade with confidence!
